Granulomatosis With Polyangiitis in a Patient on Programmed Death-1 Inhibitor for Advanced Non-small-cell Lung Cancer

Frontiers in Oncology

Romain Alfieri¹  Michelle Pirotte¹  Nancy Detrembleur²  Bernard Duysinx³  Renaud Louis³  Anne Sibille³  Olivier Malaise⁴ 

[1] Department of Internal Medicine, University Hospital of Liège, Liège, Belgium;Department of Pathology, University Hospital of Liège, Liège, Belgium;Department of Pulmonology, University Hospital of Liège, Liège, Belgium;Department of Rhumatology, University Hospital of Liège, Liège, Belgium;

关键词: immune checkpoint inhibitor;    non-small-cell lung cancer;    granulomatosis with polyangiitis;    immune-related adverse events;    anti-PD-1 antibody;   

DOI  :  10.3389/fonc.2019.00478

来源: DOAJ

【 摘 要 】

Objectives: To contribute to a precise and thorough knowledge of immune-related adverse events (irAE) induced by immune checkpoint inhibitors (ICI) and to emphasize the importance of this specific form of toxicity in terms of potential predictive value and long-term effects.Materials and Methods: We report the first case of granulomatosis with polyangiitis (GPA) in a patient treated with an anti-Programmed Death protein-1 (PD-1) antibody for advanced non-small-cell lung cancer (NSCLC).Results: After a single dose of this drug the patient showed severe myositis associated with a high anti-PR3 anti-neutrophil cytoplasmic antibody titer. Discontinuation of the anti-PD-1 and introduction of corticoids led to a remission of the irAE. Regarding tumor a partial response was noted. A year later a neutrophilic, sterile pleural exudate and cutaneous lesions appeared with the pathological findings of neutrophilic vasculitis. Retreatment with corticoids induced a new remission of symptoms. It remains unclear whether GPA was preexisting and clinically silent but revealed by the use of ICI or primarily induced by this treatment. Conclusions: irAE are rare when anti-PD-1 antibodies are used in monotherapy. They present with a distinct clinical picture and temporal course and require specific treatment. Patients with irAE usually have a favorable oncological outcome.

【 授权许可】

Unknown